Oventus CEO and founder, Dr Chris Hart was recently interviewed by Finance News Network’s Rachael Jones.
Following the release of the O2Vent® Optima device in the USA in September, Oventus is continuing to roll out its ‘lab in lab’ model for the treatment of obstructive sleep apnoea, supplying O2Vent® Optima devices directly to sleep facilities for the treatment of their patients.
In the interview, Dr Hart discusses the progress with the rollout, the impact on Oventus revenues and the key milestones the company is working towards in 2020.
To hear more on the ‘lab in lab’ agreements rollout and key milestones for 2020, click below to watch the video.
Leave a Reply